Verge Genomics and Ferrer have partnered to co-develop VRG50635, a promising AI-discovered drug for ALS treatment. Ferrer will develop and commercialize the drug in select global markets, while Verge retains U.S. rights as it advances through clinical trials.

Stream unavailable
Verge Genomics and Ferrer Collaborate to Advance ALS Drug Candidate VRG50635 Globally – Draper Decentralized – 9.19.24
Published September 19, 2024